Core Viewpoint - Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. is planning to raise approximately 1.18 billion yuan through its initial public offering (IPO) on the Sci-Tech Innovation Board, with the funds allocated for various drug development projects and working capital [2]. Group 1: Company Overview - Bai'ao Saitou was established in 2009 and operates as a preclinical Contract Research Organization (CRO) and biotechnology company [2]. - As of the signing date of the prospectus, the company is jointly controlled by Shen Yulei and Ni Jian, who hold a combined 26.8665% voting rights and are husband and wife [2]. Group 2: IPO Details - The company plans to issue 47.5 million new shares at an offering price of 26.68 yuan per share, aiming to raise a total of approximately 1.27 billion yuan [2]. - After deducting estimated issuance costs of about 122.95 million yuan (excluding tax), the net proceeds from the IPO are expected to be around 1.14 billion yuan [2]. - The funds will be used for the construction of a drug early-stage research and development service platform, antibody drug research and evaluation projects, preclinical research projects, and to supplement working capital [2].
今日申购：百奥赛图